The prevalence of IR-hypophysitis depends on the type of ICI: it is described in 9–10% of patients treated with anti-CTLA-4/PD-1 combination therapy, in 2–6% of patients with anti-CTLA-4 monotherapy and in 1% of patients with anti-PD(L)1 monotherapy (5, 6, 9). The gene discussed is CTLA4; the disease is hypophysitis.